Comparison Overview

Hikma Pharmaceuticals

VS

Bristol Myers Squibb

Hikma Pharmaceuticals

1 New Burlington Place, London, W1S 2HR, GB
Last Update: 2026-04-03
View Profile
Between 750 and 799
http://www.hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,252
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Bristol Myers Squibb

3401 Princeton Pike, Lawrence Township, 08648, US
Last Update: 2026-04-02
Between 800 and 849
http://www.bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 38,258
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
2

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/hikma-pharmaceuticals.jpeg
Hikma Pharmaceuticals
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/bristol-myers-squibb.jpeg
Bristol Myers Squibb
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Hikma Pharmaceuticals
100%
Compliance Rate
0/4 Standards Verified
Bristol Myers Squibb
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Bristol Myers Squibb in 2026.

Incident History — Hikma Pharmaceuticals (X = Date, Y = Severity)

Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Incident History — Bristol Myers Squibb (X = Date, Y = Severity)

Bristol Myers Squibb cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/hikma-pharmaceuticals.jpeg
Hikma Pharmaceuticals
Incidents

No Incident

https://images.rankiteo.com/companyimages/bristol-myers-squibb.jpeg
Bristol Myers Squibb
Incidents

Date Detected: 5/2023
Type:Cyber Attack
Attack Vector: Malware
Blog: Blog

Date Detected: 10/2020
Type:Ransomware
Blog: Blog

FAQ

Bristol Myers Squibb company demonstrates a stronger AI Cybersecurity Score compared to Hikma Pharmaceuticals company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Bristol Myers Squibb company has historically faced a number of disclosed cyber incidents, whereas Hikma Pharmaceuticals company has not reported any.

In the current year, Bristol Myers Squibb company and Hikma Pharmaceuticals company have not reported any cyber incidents.

Bristol Myers Squibb company has confirmed experiencing a ransomware attack, while Hikma Pharmaceuticals company has not reported such incidents publicly.

Neither Bristol Myers Squibb company nor Hikma Pharmaceuticals company has reported experiencing a data breach publicly.

Bristol Myers Squibb company has reported targeted cyberattacks, while Hikma Pharmaceuticals company has not reported such incidents publicly.

Neither Hikma Pharmaceuticals company nor Bristol Myers Squibb company has reported experiencing or disclosing vulnerabilities publicly.

Neither Hikma Pharmaceuticals nor Bristol Myers Squibb holds any compliance certifications.

Neither company holds any compliance certifications.

Bristol Myers Squibb company has more subsidiaries worldwide compared to Hikma Pharmaceuticals company.

Bristol Myers Squibb company employs more people globally than Hikma Pharmaceuticals company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Hikma Pharmaceuticals nor Bristol Myers Squibb holds SOC 2 Type 1 certification.

Neither Hikma Pharmaceuticals nor Bristol Myers Squibb holds SOC 2 Type 2 certification.

Neither Hikma Pharmaceuticals nor Bristol Myers Squibb holds ISO 27001 certification.

Neither Hikma Pharmaceuticals nor Bristol Myers Squibb holds PCI DSS certification.

Neither Hikma Pharmaceuticals nor Bristol Myers Squibb holds HIPAA certification.

Neither Hikma Pharmaceuticals nor Bristol Myers Squibb holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

nimiq/core-rs-albatross is a Rust implementation of the Nimiq Proof-of-Stake protocol based on the Albatross consensus algorithm. Prior to version 1.3.0, two peer-facing consensus request handlers assume that the history index is always available and call blockchain.history_store.history_index().unwrap() directly. That assumption is false by construction. HistoryStoreProxy::history_index() explicitly returns None for the valid HistoryStoreProxy::WithoutIndex state. when a full node is syncing or otherwise running without the history index, a remote peer can send RequestTransactionsProof or RequestTransactionReceiptsByAddress and trigger an Option::unwrap() panic on the request path. This issue has been patched in version 1.3.0.

Published
Date
2026-04-03
Updated
Date
2026-04-03
Risk Information
cvss3
Base: 5.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

PraisonAI is a multi-agent teams system. Prior to version 1.5.95, FileTools.download_file() in praisonaiagents validates the destination path but performs no validation on the url parameter, passing it directly to httpx.stream() with follow_redirects=True. An attacker who controls the URL can reach any host accessible from the server including cloud metadata services and internal network services. This issue has been patched in version 1.5.95.

Published
Date
2026-04-03
Updated
Date
2026-04-03
Risk Information
cvss3
Base: 8.6
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:N/A:N
References
Description

PraisonAI is a multi-agent teams system. Prior to version 4.5.97, OAuthManager.validate_token() returns True for any token not found in its internal store, which is empty by default. Any HTTP request to the MCP server with an arbitrary Bearer token is treated as authenticated, granting full access to all registered tools and agent capabilities. This issue has been patched in version 4.5.97.

Published
Date
2026-04-03
Updated
Date
2026-04-03
Risk Information
cvss3
Base: 9.1
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
References
Description

PraisonAI is a multi-agent teams system. Prior to version 4.5.97, the PraisonAI Gateway server accepts WebSocket connections at /ws and serves agent topology at /info with no authentication. Any network client can connect, enumerate registered agents, and send arbitrary messages to agents and their tool sets. This issue has been patched in version 4.5.97.

Published
Date
2026-04-03
Updated
Date
2026-04-03
Risk Information
cvss3
Base: 9.1
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
References
Description

PraisonAI is a multi-agent teams system. Prior to version 4.5.90, MCPToolIndex.search_tools() compiles a caller-supplied string directly as a Python regular expression with no validation, sanitization, or timeout. A crafted regex causes catastrophic backtracking in the re engine, blocking the Python thread for hundreds of seconds and causing a complete service outage. This issue has been patched in version 4.5.90.

Published
Date
2026-04-03
Updated
Date
2026-04-03
Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
References